A detailed history of Jpmorgan Chase & CO transactions in Biote Corp. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 17,114 shares of BTMD stock, worth $89,163. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,114
Previous 22,826 25.02%
Holding current value
$89,163
Previous $132,000 3.79%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$5.44 - $7.47 $31,073 - $42,668
-5,712 Reduced 25.02%
17,114 $127,000
Q1 2024

May 10, 2024

BUY
$3.79 - $6.91 $33,170 - $60,476
8,752 Added 62.19%
22,826 $132,000
Q3 2023

Nov 14, 2023

SELL
$4.73 - $7.83 $9,847 - $16,302
-2,082 Reduced 12.89%
14,074 $72,000
Q2 2023

Aug 11, 2023

BUY
$5.27 - $6.9 $85,142 - $111,476
16,156 New
16,156 $109,000

Others Institutions Holding BTMD

About biote Corp.


  • Ticker BTMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 7,574,270
  • Market Cap $39.5M
  • Description
  • biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biot...
More about BTMD
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.